Tag Archives: Pharmaceutical industry

Venture Funding of Biotech is VERY Concentrated… and Very Limited

Posted on March 9, 2014 by Alexander Szewczak

Fierce Biotech has released their latest analysis of venture capital funding of biotech in the U.S. last year, broken down by metropolitan area: Source: http://www.fiercebiotech.com/story/top-15-cities-biotech-venture-funding/2014-03-06 San Francisco is back out in front, edging out Boston-Cambridge.  After San Diego and Washington, funding … Continue reading →

Posted in Biotech, Innovation, Research | Tagged , , , , , , | Leave a comment

Hitting the fundamental limit of the drug industry?

Posted on January 28, 2014 by Alexander Szewczak

After a banner year in 2012, the number of FDA Drug approvals dropped back to 27 for 2013, a number more in line with the average rate of approvals for the last few years. As many observers have commented, the … Continue reading →

Posted in Fixing Big Pharma Research | Tagged , | 1 Comment

Fixing Big Pharma Research: Expected cost savings have to be recoverable

Posted on September 7, 2013 by Alexander Szewczak

All too often the cost savings from efficiency improvements of various kinds are dramatically over estimated, especially when large numbers of small improvements are aggregated. Companies of all kinds (not just Pharma) often justify investments in new equipment or software … Continue reading →

Posted in Fixing Big Pharma Research, Management | Tagged , , , , , | Leave a comment

Fixing Big Pharma Research: The costs of delays need to be properly valued

Posted on September 6, 2013 by Alexander Szewczak

For the Pharmaceutical industry, the foregone revenue created by delays in bringing a drug to market can be surprisingly high — from $50,000 to $2,000,000 per day, depending on the phase of the pipeline. Such costs are often under appreciated. … Continue reading →

Posted in Management, Research | Tagged , , , | Leave a comment

Fixing Big Pharma Research: Introduction

Posted on September 6, 2013 by Alexander Szewczak

Lots of articles and blog posts get written about the research productivity crisis in the pharmaceutical industry.  A lot of Wall Street types argue that Pharma companies simply must spend less on R&D (Recently, yet another analyst called for a … Continue reading →

Posted in Research | Tagged , , , , , , | 1 Comment